CG Results Healthcare has advised Novartis on the divestment of its Boucherville, Canada manufacturing facility

  • Service: M&A
  • Sector: Healthcare
  • Sub Sector: Pharma & Biotech, CROs & CMOs
  • Engagement Type: Sell Side
Mar 2022
has divested its Boucherville, Canada manufacturing facility

Novartis has divested its sterile fill/finish facility located in Boucherville, Canada to Delpharm, a leading contract development and manufacturing organisation with 18 plants in France, Italy, Belgium, Canada, Poland and The Netherlands. The Boucherville plant will allow Delpharm to conduct sterile vial and ampoule manufacturing in North America.

This deal represents CG Results’ 7th deal advising Novartis over the past 2 years.

Sector Related Deals

Jul 2022
has divested its API site in Rhode Island, USA, to
Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monoclonal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has invested in
company name confidential
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
Jun 2021
has acquired a drug product manufacturing facility from